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In his letter Cunha suggests that oral antibiotic therapy is safer and less 
expensive than intravenous therapy via central venous catheters (CVCs) (1). The 
implication is that costs will fall and increased health benefits will be enjoyed resulting 
in a gain in efficiency within the healthcare system. CVCs are often used in critically ill 
patients to deliver antimicrobial therapy, but expose patients to a risk of catheter-related 
bloodstream infection (CRBSI). Our current knowledge about the efficiency (i.e. cost-
effectiveness) of allocating resources toward interventions that prevent CRBSI in 
patients requiring a CVC has already been reviewed (2). If for some patient groups 
antimicrobial therapy can be delivered orally, instead of through a CVC, then the costs 
and benefits of this alternate strategy should be evaluated.  
Like any decision that involves the reallocation of resources toward a different 
clinical practice, this decision should not be based on instinct but subjected to a rigorous 
economic appraisal using a cost-effectiveness framework. The decision requires 
consideration of all relevant alternative modes of delivery in order to identify which is 
the most cost-effective. Depending on the clinical context, options may include delivery 
via CVCs, delivery via peripheral lines, use of an intravenous to oral switch therapy, or 
oral administration using a variety of dosing schedules.  
To undertake an evaluation to identify the most efficient mode of antimicrobial 
delivery, would require input from clinical experts to focus the context of the decision 
problem. All relevant costs and benefits of each option should be specified, and each 
mode of delivery compared on a common outcome such as the incremental cost per 
quality-adjusted life year. It is important that not just the financial costs or cost-savings 
are considered (3). Having identified the “best” option given our current understanding 
of the problem, it would then be imperative to incorporate the residual uncertainty 
surrounding this choice into the evaluation to explore the level of confidence in the 
decision and identify what future research would best inform this problem (4). 
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